Transfusion Support in Hematopoietic Stem Cell Transplantation: A Contemporary Narrative Review.
Brian David AdkinsJeremy W JacobsGarrett S BoothBipin P SavaniLaura D StephensPublished in: Clinical hematology international (2024)
Hematopoietic stem cell transplantation (HSCT) is a cornerstone of modern medical practice, and can only be performed safely and effectively with appropriate transfusion medicine support. Patients undergoing HSCT often develop therapy-related cytopenia, necessitating differing blood product requirements in the pre-, peri-, and post-transplant periods. Moreover, ensuring optimal management for patients alloimmunized to human leukocyte antigens (HLA) and/or red blood cell (RBC) antigens, as well as for patients receiving ABO-incompatible transplants, requires close collaboration with transfusion medicine and blood bank professionals. Finally, as updated transfusion guidelines and novel blood product modifications emerge, the options available to the transplant practitioner continue to expand. Herein, we detail contemporary blood transfusion and transfusion medicine practices for patients undergoing HSCT.
Keyphrases
- cardiac surgery
- patients undergoing
- red blood cell
- healthcare
- sickle cell disease
- primary care
- end stage renal disease
- endothelial cells
- acute myeloid leukemia
- acute kidney injury
- hematopoietic stem cell
- newly diagnosed
- ejection fraction
- dendritic cells
- chronic kidney disease
- prognostic factors
- patient reported outcomes
- mesenchymal stem cells
- quality improvement
- drug induced